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Summary Background Efatutazone, a novel oral highly-
selective peroxisome proliferator-activated receptor gamma
(PPARγ) agonist, has demonstrated some inhibitory effects on
disease stabilization in patients with metastatic colorectal cancer
(mCRC) enrolled in previous phase I studies. Here, we evaluate
the safety and pharmacokinetics of efatutazone combined with
FOLFIRI (5-fluorouracil, levo-leucovorin, and irinotecan) as
second-line chemotherapy in Japanese patients with mCRC.
Methods Dose-limiting toxicities (DLTs) were evaluated at 2
efatutazone dose levels of 0.25 and 0.50 mg (the recommended
dose [RD] of efatutazone monotherapy) twice daily in combi-
nation with FOLFIRI in a 3–9 patient cohort. Furthermore,
tolerability at the RD level was assessed in additional patients,
up to 12 in total. Blood samples for pharmacokinetics and
biomarkers and tumor samples for archival tissues were collect-
ed from all patients.Results Fifteen patients (0.25mg, 3; 0.5mg,
12) were enrolled. No DLTs were observed. Most patients
experienced weight increase (100 %) and edema (80.0 %),
which were manageable with diuretics. Common grade 3/4
toxicities were neutropenia (93.3 %), leukopenia (46.7 %), and
anemia (33.3 %). Stable disease was observed in 8 of the 14
patients evaluable for tumor response. The plasma adiponectin
levels increased over time and increased dose. No clear relation-
ship was detected between treatment efficacies and plasma
levels of adiponectin as well as the expression levels of PPARγ
and the retinoid X receptor in tumor tissues. Conclusions
Efatutazone combined with FOLFIRI demonstrates an accept-
able safety profile and evidence of disease stabilization in Jap-
anese patients with mCRC. The RD for efatutazone monother-
apy can be used in combination with FOLFIRI.
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Introduction
Peroxisome proliferator-activated receptor gamma
(PPARγ) is a member of the nuclear hormone receptor
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superfamily. It is activated through its ligands and is in-
volved in the regulation of inflammation, cell cycle pro-
gression, cell proliferation, apoptosis, carcinogenesis, and
angiogenesis [1–4]. Preclinical studies demonstrated syn-
ergistic or additive effects of PPARγ ligands with chemo-
therapeutic agents on cancer cell apoptosis and growth
inhibition, and suggested their potential clinical use in
cancer therapy [4–7].
Efatutazone, a novel oral highly-selective thiazolidinedione
PPARγ agonist, shows greater potency than second-generation
thiazolidinediones such as pioglitazone [8]. In preclinical tumor
models, proliferation of human anaplastic thyroid carcinoma
and pancreatic tumor cell lines were inhibited in vitro , and
human colorectal cancer (CRC) and anaplastic thyroid carcino-
ma cell xenografts were inhibited in nude rodents [9, 10].
PPARγ activity-related adiponectin is also considered a useful
biomarker of carcinogenesis and progression of colorectal ad-
enoma [11].
A US Phase 1 study of efatutazone monotherapy in patients
with advanced solid malignancies demonstrated acceptable
safety and evidence of antitumor activity [12]. A similar study
in Japanese patients with metastatic solid tumors confirmed
the results (presented in a poster session at the 36th Congress
of the European Society for Medical Oncology, 2011) that
efatutazone is potentially effective against CRC, by achieving
sustained disease stabilization.
In the clinical setting, FOLFOX (5-fluorouracil, levo-
leucovorin, and oxaliplatin), CapeOX (capecitabine and
oxaliplatin) and FOLFIRI (5-fluorouracil, levo-leucovorin,
and irinotecan) regimens are global standard therapies for
CRC, demonstrating efficacy and tolerability, and are often
chosen as first- and second-line therapies, respectively [13,
14]. The combination of PPARγ ligands with existing che-
motherapy is reported to be beneficial for cancer prevention
and therapy [4–7], and a novel combination with greater
clinical efficacy against advanced refractory tumors including
metastatic CRC (mCRC) is needed.
This Phase 1 study was designed to evaluate the safety
profile and pharmacokinetics of efatutazone in combination
with FOLFIRI as second-line therapy in Japanese patients
with mCRC. Secondary objectives included assessment of
the preliminary antitumor efficacy of efatutazone, assessment
of potential biomarkers of efatutazone including plasma
adiponectin, and to determine the recommended dose (RD)
of efatutazone in combination with FOLFIRI.
Materials and methods
Study design
This Phase 1, open-label, dose-escalation study was con-
ducted at 3 medical centers in Japan between September
2010 and June 2012 (JapicCTI-101230; Clinical Trials
Information/JapicCTI, http://www.clinicaltrials.jp/user/
cteSearch_e.jsp). It was performed in accordance with
the International Conference on Harmonisation Good
Clinical Practice Guidelines, the principle of the
Declaration of Helsinki and all applicable laws and
regulations in Japan. The protocol was reviewed and
approved by the Institutional Review Boards of all
participating study sites. All patients provided written
informed consent before enrollment.
The dose-escalation study had a 3+3 design and 2 steps.
Since previous Phase 1 studies had indicated an RD of
0.50 mg twice daily (BID) for 4 weeks, we assessed 2 doses
of efatutazone, namely, 0.25 and 0.50 mg BID for 4 weeks
(1 cycle) in combination with FOLFIRI (irinotecan 180 mg/
m2 intravenous [IV] infusion over 90 min or longer, levo-
leucovorin 200 mg/m2 IV infusion over 120 min, and 5-
fluorouracil IV continuous infusion 2400 mg/m2 over 46 h)
once every 2 weeks, in 3 to 9 patients each in Step 1 (dose-
escalation phase for evaluation of dose-limiting toxicity
[DLT]).
DLTs were defined as follows: (a) grade 3 or higher neu-
tropenia complicated by fever≥38.5 °C or infection, or grade
4 neutropenia with a duration of 7 days or longer; (b) grade 4
thrombocytopenia, or grade 3 thrombocytopenia requiring
transfusion; (c) grade 4 anemia; (d) grade 3 or higher pleural
or pericardial effusion, peripheral edema or ascites unrespon-
sive to treatment; (e) uncontrollable grade 3 or higher severe
fatigue, anorexia, nausea, vomiting or diarrhea, despite max-
imal supportive therapy; (f) any other grade 3 or higher
toxicities than those described in definitions (d) and (e), except
for fever without neutropenia and transient electrolyte
abnormality.
According to the protocol, if 1 of the first 3 patients at
a dose level would experience a DLT, 3 more patients
would be enrolled. In case of no DLTs in 3 patients or a
maximum of 1 DLT in 6 patients, the study would
proceed to the next dose level. In case of 2 DLTs in 6
patients, another 3 patients would be enrolled. RD was
based on the Step 1 safety data, and would be adminis-
tered in combination with FOLFIRI to up to 9 additional
patients in Step 2. Administration of efatutazone and
FOLFIRI would continue until disease progression or
unacceptable toxicity was observed, and then efatutazone
and FOLFIRI doses would be reduced based on set
guidelines.
Study population
Inclusion criteria were: age≥20 years; histologically/
cytologically confirmed mCRC after failure of first-line
chemotherapy; an Eastern Cooperative Oncology Group
(ECOG) performance status score of 0 or 1; a
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measurable lesion; life expectancy of at least 3 months;
adequate organ and bone marrow functions documented
within 7 days before enrollment, and no blood transfu-
sions within 1 month before enrollment; resolution of
toxic effects of prior therapy (except alopecia) to grade
0 or 1 according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (NCI-
CTCAE), Version 3.0.
Exclusion criteria were: previous irinotecan-based first-line
chemotherapy and preexisting severe fluid retention including
(edema, pleural effusion and ascites).
Safety assessment
Safety was assessed at each study visit (every week for
2 cycles, then every 2 weeks) by monitoring adverse
events (AEs) and clinical laboratory evaluations. Patients
were evaluated for efatutazone-related DLTs in Step 1
(Cycle 1). AEs and laboratory test results were graded
according to NCI-CTCAE, Version 3.0.
Efficacy assessment
Computed tomography or magnetic resonance imaging was
performed every 2 cycles for efficacy assessment.
Tumor response was evaluated according to the Response
Evaluation Criteria in Solid Tumors, Version 1.1. Overall
response rate (ORR) and disease control rate (DCR) were
calculated. Progression-free survival (PFS) was defined as
time from enrollment to the detection of progressive disease
(PD) or death (or the date of last tumor evaluation in stable
patients).
Pharmacokinetics
Blood samples were collected on Day 1 (Cycles 1 and 2) at the
following time points: predose (immediately before the morn-
ing dose of efatutazone) and postdose (0.5, 1, 2, 3, 4, 6 and 8 to
10 h). Additional samples were collected predose on Days 8
and 15 (Cycle 1). Validated liquid chromatography-tandem
mass spectrometry was used to measure the plasma concentra-
tion of the free form of efatutazone. The plasma concentration
Table 1 Baseline characteristics
(Safety analysis set)
Values represent the number (%)
of subjects
BID twice daily, ECOG Eastern
Cooperative Oncology Group, n
number of subjects
a One subject had UGT1A1 *6/*6
genotype
bOne subject had UGT1A1 *28/
*28 genotype
Characteristic Treatment cohort
0.25 mg BID 0.50 mg BID Overall
(n =3) (n =12) (n =15)
Median age in years 63 64 63
(range) (56–64) (41–73) (41–73)
Gender
Male 1 (33.3) 6 (50.0) 7 (46.7)
Female 2 (66.7) 6 (50.0) 8 (53.3)
ECOG performance status
0 2 (66.7) 8 (66.7) 10 (66.7)
1 1 (33.3) 4 (33.3) 5 (33.3)
Primary site
Rectum 3 (100.0) 7 (58.3) 10 (66.7)
Colon 0 4 (33.3) 4 (26.7)
Colon and rectum 0 1 (8.3) 1 (6.7)
Histological type
Well differentiated 2 (66.7) 4 (33.3) 6 (40.0)
Moderately differentiated 1 (33.3) 6 (50.0) 7 (46.7)
Poorly differentiated 0 1 (8.3) 1 (6.7)
Others 0 1 (8.3) 1 (6.7)
Previous chemotherapy
Oxaliplatin-based regimen 2 (66.7) 1 (8.3) 3 (20.0)
Oxaliplatin-based regimen+bevacizumab 0 11 (91.7) 11 (73.3)
Capecitabine monotherapy 1 (33.3) 0 1 (6.7)
UGT1A1 genotype
Wild (*1/*1) 1 (33.3) 7 (58.3) 8 (66.7)
Heterozygous (*1/*28, *1/*6) 1 (33.3) 4 (33.3) 5 (33.3)
Homozygous (*28/*28, *6/*6, *28/*6) 1 (33.3)a 1 (8.3)b 2 (13.3)
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of an active metabolite of irinotecan (SN-38) was also mea-
sured immediately after irinotecan hydrochloride (CPT-11)
administration in the morning on Day 1 (Cycles 1 and 2).
Biomarkers
Blood samples for the measurement of plasma adiponectin
were collected predose on Days 1, 8 and 15 in Cycle 1, and
Day 1 in Cycles 2, 3 and 4. Plasma adiponectin concentrations
were determined by quantitative sandwich enzyme immuno-
assay kit (Quantikine®, R&D systems, Inc., Minneapolis,
MN, the USA).
Expression levels of PPARγ and retinoid X receptor
(RXR) in archived tumor specimens were studied by
immunohistochemistry using PPARγ (C26H12) Rabbit
mAb (Cell Signaling Technology, Inc., Danvers, MA,
the USA) and Rabbit Anti-Human Retinoic X Receptor
Gamma Polyclonal Antibody (Spring Bioscience, Inc.,
Pleasanton, CA, the USA), respectively.
Results
Patient demographics
A total of 15 patients were enrolled and received efatutazone
treatment in combination with FOLFIRI. In Step 1, 2 cohorts
with 3 patients each received efatutazone at 0.25 and 0.50 mg
BID, respectively. In Step 2, an additional 9 patients received
efatutazone 0.50 mg BID.
Enrollment started in September 2010, and 15 patients
were enrolled by March 2012. Baseline patient characteristics
are summarized in Table 1. UGT1A1 genotypes, included 1
homozygous *6/*6 genotype, and 1 homozygous *28/*28
genotype.
Safety
Overall, efatutazone showed acceptable safety at both 0.25
and 0.50 mg BID. No DLTs were observed during the
Table 2 Summary of treatment-
emergent adverse events that oc-
curred in 3 or more patients
throughout the study (Safety
analysis set)
Values represent the number (%)
of subjects
MedDRA Medical Dictionary for
Regulatory Activities
MedDRA Preferred term Treatment-emergent Efatutazone-related
Overall Grade 3 or higher Overall Grade 3 or higher
Hematotoxicity
Neutropenia 15 (100.0) 14 (93.3) 7 (46.7) 6 (40.0)
Leukopenia 14 (93.3) 7 (46.7) 6 (40.0) 2 (13.3)
Anemia 13 (86.7) 5 (33.3) 11 (73.3) 4 (26.7)
Thrombocytopenia 10 (66.7) 1 (6.7) 3 (20.0) 1 (6.7)
Non-hematotoxicity
Weight increase 15 (100.0) 0 15 (100.0) 0
Edema 12 (80.0) 1 (6.7) 10 (66.7) 1 (6.7)
Nausea 9 (60.0) 0 0 0
Vomiting 8 (53.3) 0 0 0
Alopecia 8 (53.3) 0 0 0
Fatigue 8 (53.3) 1 (6.7) 3 (20.0) 1 (6.7)
Decreased appetite 7 (46.7) 1 (6.7) 2 (13.3) 0
Diarrhea 7 (46.7) 0 1 (6.7) 0
Hypoalbuminemia 6 (40.0) 2 (13.3) 2 (13.3) 0
Constipation 5 (33.3) 0 3 (20.0) 0
Blood alkaline phosphatase increased 5 (33.3) 1 (6.7) 0 0
Blood creatinine increased 5 (33.3) 0 1 (6.7) 0
Hypercholesterolemia 4 (26.7) 1 (6.7) 3 (20.0) 0
Hyponatremia 4 (26.7) 1 (6.7) 4 (26.7) 1 (6.7)
Abdominal pain 4 (26.7) 1 (6.7) 2 (13.3) 0
Pyrexia 4 (26.7) 0 1 (6.7) 0
Gamma-glutamyltransferase
increased
4 (26.7) 2 (13.3) 0 0
Nasopharyngitis 3 (20.0) 0 1 (6.7) 0
Stomatitis 3 (20.0) 0 1 (6.7) 0
Malaise 3 (20.0) 1 (6.7) 2 (13.3) 1 (6.7)
Aspartate aminotransferase increased 3 (20.0) 0 0 0
476 Invest New Drugs (2014) 32:473–480
0.25 mg BID
0.50 mg BID
PD SD PD SD SD SD SD SD
PD PD PD SD PD SD







































Fig. 1 Waterfall plot of the best
percent changes from baseline in
the target lesion. Best percent
change from baseline (%) in the
target lesion=([the minimum sum
of the longest diameters at all
measurement time points−the
sum of the longest diameters at
baseline] / [the sum of the longest
diameters at baseline])×100. BID
twice daily, PD progressive
disease, SD stable disease
0.25 mg BID, Day 1, Cycle 1
0.50 mg BID, Day 1, Cycle 1
Limit of quantitation = 1 (ng/ml)
0.25 mg BID, Day 1, Cycle 2
0.50 mg BID, Day 1, Cycle 2
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Fig. 2 Concentration-time curve
of the free form of efatutazone
following oral dosing on Day 1 in
Cycle 1 (single dose [a]) and Day
1 in Cycle 2 (repeated dose [b]).
BID twice daily
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evaluation period (Cycle 1, Step 1). The median duration
(range) of efatutazone treatment was 152.0 (71–157) days in
the 0.25 mg BID group, 62.5 (21–241) days in the 0.50 mg
BID group, and 67.0 (21–241) days in the overall study
population.
Treatment-emergent AEs (TEAEs) that occurred in 3 or
more patients throughout the study period are summarized in
Table 2. Most patients experienced weight increase (100 %)
and edema (80.0 %), usually at a severity of≤grade 2. These
were managed with diuretics. Common grade 3/4 toxicities
were neutropenia (93.3 %), leukopenia (46.7 %) and anemia
(33.3 %), and were managed with supportive therapy and/or
FOLFIRI modification.
A total of 14 (93.3 %) patients experienced at least 1
grade 3 or more severe TEAE: 3 (100 %) in the 0.25 BID
group, and 11 (91.7 %) in the 0.50 mg BID groups. In the
0.25 mg BID group, 1 patient experienced grade 3 edema
(44 days after the first administration of efatutazone), which
was related to efatutazone and recovered with diuretics and
temporary discontinuation of efatutazone. No patients ex-
perienced grade 3 or more severe weight increase. Five
patients (including 2 patients with an UGT1A1 homozy-
gous genotype) experienced grade 4 neutropenia (< 7 days
duration), and 1 patient experienced grade 4 thrombocyto-
penia and grade 4 anemia.
No deaths were reported throughout the study period. Five
patients (33.3 %) discontinued the study due to efatutazone-
related TEAEs (fatigue, bronchitis, edema, anemia, and inter-
stitial pneumonia). Three patients (20.0 %) experienced seri-
ous TEAEs related to both efatutazone and FOLFIRI, but no
serious TEAEs during the DLTevaluation period. One patient
on 0.25 mg BID had grade 3 fatigue and grade 2 bronchitis on
Day 71. The study drugs were discontinued, and the patient
received oxygen inhalation and antimicrobials, recovered of
the fatigue and had relief of the bronchitis by Day 79. One
patient on 0.50 mg BID had grade 3 interstitial pneumonia on
Day 35. The study drugs were discontinued, steroid pulse
therapy and antimicrobials were administered, and the patient
experienced relief of the interstitial pneumonia by Day 55.
One patient on 0.50 mg BID had grade 3 febrile neutropenia
on Day 36, and grade 4 anemia and grade 4 neutropenia on
Day 37. The patient received platelet transfusion, antimicro-
bials and granulocyte colony-stimulating factor for the ane-
mia. Fever improved by Day 40 and anemia and neutropenia
by Day 43.
Efficacy
A total of 14 patients were evaluable for efficacy analysis,
with ORR of 0 %, and DCR of 57.1 % (95 % confidence
interval [CI]: 28.9, 82.3). Five (45.5 %) of 11 patients on
efatutazone 0.50 mg BID had stable disease (SD). Awaterfall
Table 3 Summary of pharmacokinetic parameters (Pharmacokinetic analysis set)
Parameter 0.25 mg BID 0.50 mg BID
Day 1 in Cycle 1a (n =3) Day 1 in Cycle 2b (n =3) Day 1 in Cycle 1a (n =12) Day 1 in Cycle 2b (n =6)
Cmax (ng/ml) 10.1 (9.5) 18.3 (13.2) 22.2 (7.97) 35.5 (14.7)
Tmax (hours) 4.03 (2.00–8.03) 3.25 (1.98–3.95) 4.08 (1.97–6.00) 2.99 (1.97–4.03)
AUClast (ng h/ml) 60.9 (66.9) 125 (85.0) 127 (52.9) 255 (105)
AUCtau (ng h/ml) 116 (99.3) 159 (110) 193 (66.5) 325 (154)
Ctrough (ng/ml) – 8.68 (5.91) – 21.1 (10.8)
For Cmax, AUClast, AUCtau, and Ctrough, values represent the means (standard deviation)
For Tmax, values represent the median (range)
AUClast area under the concentration-time curve from zero to the last quantifiable concentration, AUCtau area under the concentration-time curve during
the dosing interval, BID twice daily, Cmax maximum plasma concentration, Ctrough trough plasma concentration, n number of subjects, Tmax time to
reach the maximum plasma concentration
a Following single-dose administration
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Fig. 3 Time course of plasma adiponectin levels. BID twice daily
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plot of the best percentage changes from baseline in the target
lesion is shown in Fig. 1.
Median (95 % CI) PFS was 158.5 (158–159) days in the
0.25 mg BID group, 73.0 (65–235) days in the 0.50 mg BID
group, and 85.0 (70–159) days in the overall study population.
Pharmacokinetics
Plasma concentration-time curves following administration
on Day 1 (Cycles 1 and 2) are shown in Fig. 2. Although an
absorption lag usually followed single-dose administration in
the 0.50 mg cohort, the mean plasma concentration of
efatutazone generally increased with repeated doses.
Pharmacokinetic values of the free form of efatutazone
following oral administration on Day 1 (Cycles 1 and 2) are
shown in Table 3. The Cmax and AUCtau in patients treated
with efatutazone 0.50 mg were approximately 2 times those in
patients treated with efatutazone 0.25 mg.
The trough plasma concentration did not increase with
repeated doses.
Biomarkers
The plasma adiponectin levels increased over time and in-
creased dose as shown in Fig. 3.
There were no apparent differences in the PPARγ expres-
sion levels in archived tumor specimens between patients with
SD and those with PD (Mean [range] H scores in nucleus,
106.4 [5–180] versus 155.8 [5–240]; H score=∑[the staining
intensity×the occupied percentage of positive cells]). RXR
expression levels were not significantly different in the nucle-
us H scores between patients with SD and those with PD (20.0
[0–70] versus 25.0 [0–75]).
Discussion
This is the first study of efatutazone combined with
FOLFIRI evaluating the safety profile and pharmacokinet-
ics of efatutazone as second-line therapy in Japanese pa-
tients with mCRC. The safety profile in this study is con-
sistent with that in previous Phase 1 studies (Ref. [12] and
the poster presentation mentioned in the “Introduction”).
Compared with the toxicity data of FOLFIRI as second-line
chemotherapy for mCRC reported in a FIRIS (IRIS
[irinotecan plus S-1] versus FOLFIRI) study [14], the tox-
icity profile of efatutazone plus FOLFIRI was almost iden-
tical to that of FOLFIRI alone, adverse effects including
hematotoxicity were more frequent with efatutazone com-
bined with FOLFIRI than with FOLFIRI alone. This higher
incidences of adverse effects may partly be attributable to
the initial irinotecan IV infusion dose (180 mg/m2) admin-
istered in this study, which is rather high for ethnic Japanese
patients. In the FIRIS study, irinotecan 150 mg/m2 IV
infusion was used [14]. Most adverse effects, including
hematotoxicity, were manageable with supportive therapy
and discontinuation/modification of efatutazone and/or
FOLFIRI.
Preliminary efficacy results appeared to be comparable
with those of second-line FOLFIRI therapy for advanced
CRC (4 % PR, 30 % SD) reported in a randomized
GERCOR study (randomized control study with FOLFIRI
and FOLFOX) [13]. In a previous US Phase 1 study in 27
patients with advanced solid malignancies, 1 (3.7 %) pa-
tient with myxoid liposarcoma achieved sustained PR
(690 days on treatment), and 10 (37.0 %) patients had SD
for≥60 days [12]. In a Japanese Phase 1 study in 13 patients
with metastatic solid tumors, 1 (7.7 %) patient with thymic
cancer achieved unconfirmed PR (> 210 days on treat-
ment), and 3 (23.1 %) patients had SD (75–170 days on
treatment) (the poster presentation mentioned in the “Intro-
duction”). Based on the efficacy results of the present and
previous Phase 1 studies, efatutazone is a potential clini-
cally useful anticancer drug.
Efatutazone did not affect plasma concentrations of SN-
38 (data not shown). Adiponectin is secreted by adipocytes
in response to PPARγ agonist-induced gene expression in
humans and rodents [15]. Since the plasma adiponectin
level in colorectal adenoma patients is significantly lower
than age-, sex-, and body mass index-matched non-cancer
controls, it is considered a good biomarker for carcinogen-
esis and progression of colorectal adenoma [11]. Patients
whose plasma adiponectin concentration reached≥100 μg/
mL tended to have longer PFS than patients with
adiponectin<100 μg/mL (mean [range] PFS, 106.9 [26–
235] versus 60.6 [36–76] days). The clinical relevance of
increased adiponectin levels and efatutazone treatment has
to be studied further.
In a US Phase 1 study, archived tumor specimens of pa-
tients with SD or PR showed significantly higher PPARγ and
RXR expression than those with PD [12]. In the present study,
such differences could not be confirmed.
In conclusion, efatutazone at doses of 0.25 and
0.50 mg BID in combination with FOLFIRI demon-
strates an acceptable safety profile and evidence of dis-
ease control in Japanese patients with mCRC. The RD in
combination with FOLFIRI is 0.50 mg BID. The results
of a randomized Phase 2 study of efatutazone in combi-
nation with FOLFIRI compared with FOLFIRI alone will
also be reported soon.
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